Clinical trials: Myeloma-Multiple
Multiple Myeloma
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
- Trial name
- BMS TIME-1 (NCT00546780)
- Testing
- Tanespimycin, Bortezomib
- Where
- 19 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Myeloma, Multiple
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT), safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Bortezomib and Dexamethasone in patients…
- Trial name
- NCT03051841
- Testing
- CKD-581
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Relapsed/Refractory Multiple Myeloma
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199…
- Trial name
- NCT01794520
- Testing
- Venetoclax, Dexamethasone
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- AbbVie
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
- Trial name
- CANDOR (NCT03158688)
- Testing
- Dexamethasone, Daratumumab, Carfilzomib
- Where
- 113 sites in United States, Australia and 17 more
- Volunteers
- 466 people
- Sponsor
- Amgen
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting…
- Trial name
- NCT04280328
- Testing
- Ciforadenant, daratumumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Multiple Myeloma, Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36…
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Trial name
- NCT05651932
- Testing
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 165 people
- Sponsor
- K36 Therapeutics, Inc.
Relapsed/ Refractory Multiple Myeloma
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
- Trial name
- NCT03445663
- Testing
- AMG 424
- Where
- 8 sites in United States, Australia
- Volunteers
- 27 people
- Sponsor
- Xencor, Inc.
Multiple Myeloma
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.
- Trial name
- NCT00087867
- Testing
- SCIO-469, SCIO-469 and bortezomib
- Volunteers
- 62 people
- Sponsor
- Scios, Inc.
Multiple Myeloma
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.
- Trial name
- CARTIFAN-1 (NCT03758417)
- Testing
- LCAR-B38M CAR-T Cell
- Where
- 11 sites in China
- Volunteers
- 123 people
- Sponsor
- Nanjing Legend Biotech Co.
Multiple Myeloma
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
This study aims to assess the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.
- Trial name
- NCT02916420
- Testing
- Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
One purpose of this study is to evaluate the effectiveness and safety in long term treatment for patients who completed preceding phase I/II study.
- Trial name
- NCT00216697
- Testing
- bortezomib
- Volunteers
- 13 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this phase 3 study is to determine if subcutaneous velcade is non-inferior to intravenous velcade when administered in combination with low-dose dexamethasone in chinese refractory or relapsed multiple myeloma…
- Trial name
- NCT02811978
- Testing
- Bortezomib, Dexamethasone
- Where
- 10 sites in China
- Volunteers
- 81 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, first in human, study to evaluate the safety and the effects of in vivo BCMA-CAR T cell therapy (VV169) in patients with Multiple Myeloma that has been previously treated and has come back, or does not respond to…
- Trial name
- NCT07802717
- Testing
- VV169
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vyriad, Inc.
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
A Study of VLX1570 and Dexamethasone in Myeloma Patients
This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02372240
- Testing
- VLX1570 and dexamethasone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vivolux AB
Drug Safety
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Primary To evaluate the safety and tolerability of escalating doses of an intravenous (i.v.) infusion of PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT01727778
- Testing
- Anti-GRP78 monoclonal IgM antibody PAT-SM6
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Patrys Ltd.
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.